Isradipine inhibits PMN leukocyte function. A possible interference with the adenosine system.
The dihydropyridine derivative isradipine is able to inhibit PMN leukocyte function, such as enzyme release and free radical generation, following the activation with specific stimuli. Moreover, the drug prevents calcium influx into the cells as detected by the specific fluorescent dye FURA 2/acetoxymethylester. The specific adenosine receptor antagonist theophylline is able to partially remove the inhibiting activity, thus suggesting a possible interference of isradipine with the adenosine system. Such a cell-protecting activity adds further rationale to the employment of isradipine in those conditions, such as acute and chronic ischaemia and reperfusion damage, in which PMN leukocyte-dependent tissue injury represents a relevant pathogenetic mechanism.
Institute of Clinical Medicine, University of Siena School of Medicine, Policlinico Le Scotte, Italy.
P L
PL
Capecchi
F
F
Laghi Pasini
L
L
Ceccatelli
T
T
Di Perri
D000241:Adenosine / Q000378:metabolism*; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D005966:Glucuronidase / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D017275:Isradipine / Q000494:pharmacology*; D009113:Muramidase / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D015427:Reperfusion Injury / Q000209:etiology / Q000517:prevention & control; D013481:Superoxides / Q000378:metabolism; D013806:Theophylline / Q000494:pharmacology
D013481:Superoxides; D000001:Calcimycin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D013806:Theophylline; D009113:Muramidase; D005966:Glucuronidase; D000241:Adenosine; D002118:Calcium; D017275:Isradipine